Citius pharmaceuticals announces fda acceptance of the bla resubmission of lymphir™ (denileukin diftitox) for the treatment of adults with relapsed or refractory cutaneous t-cell lymphoma

Fda assigns prescription drug user fee act (pdufa) target action date of august 13, 2024 cranford, n.j., march 18, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that the u.s. food and drug administration (fda) has accepted the resubmission of the company's biologics license application (bla) for lymphir™ (denileukin diftitox), an il-2-based immunotherapy for the treatment of patients with relapsed or refractory cutaneous t-cell lymphoma (ctcl) after at least one prior systemic therapy.
CTXR Ratings Summary
CTXR Quant Ranking